RxDoctor Payments Data

Magdalena Orchard

Family · Honesdale, PANPI 1356005565

Payments from drug & device makers

$3,196in general payments, 2019–2025

Across 149 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$563
  • AbbVie$476
  • Novo Nordisk$390
  • GSK$303
  • Lilly USA, LLC$268
  • Sage Therapeutics, LLC$197
  • plus $1000 from 24 others

What the payments were for

  • Food & beverage$3,196100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,196 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$115,902
EliquisApixaban92$72,282
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$70,011
JardianceEmpagliflozin47$38,492
XareltoRivaroxaban41$37,195
TrulicityDulaglutide20$34,516
TradjentaLinagliptin24$20,335
JanuviaSitagliptin Phosphate18$19,022
FarxigaDapagliflozin Propanediol12$16,854
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$10,806
Breo ElliptaFluticasone/Vilanterol18$10,165
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$9,987
Fenofibrate23$8,825
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$7,415
SymbicortBudesonide/Formoterol Fumarate19$5,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$390$115,902121 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$303$85,699101 claims
PfizerEliquis$76$72,28292 claims
Boehringer IngelheimJardiance, Tradjenta$80$58,82771 claims
Lilly USA, LLCTrulicity$268$34,51620 claims
AstraZenecaFarxiga, Symbicort$87$22,50831 claims
MerckJanuvia$15$19,02218 claims
AbbVieSynthroid, Armour Thyroid$476$2,32030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Honesdale

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →